Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.49 |
| ▸ | MMP3 | P08254 | 12/20 | 0.49 |
| ▸ | MMP9 | P14780 | 5/20 | 0.49 |
| ▸ | MMP14 | P50281 | 5/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111098 | 0.88 | MMP2 (0.44) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6449147 | 0.82 | MMP2 (0.70) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6437736 | 0.76 | MMP2 (0.44) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7116159 | 0.75 | MMP2 (0.48) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7110080 | 0.73 | MMP2 (0.42) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7109315 | 0.73 | MMP2 (0.44) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7112585 | 0.72 | MMP2 (0.39) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7110076 | 0.69 | MMP2 (0.72) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6436791 | 0.69 | MMP2 (0.66) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7111108 | 0.67 | MMP2 (0.48) | MMP2MMP3MMP9MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047665-B1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-10-22 | — | — | EP | claimed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1047665-B1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885MMP9 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.